| Original language | English |
|---|---|
| Pages (from-to) | 193-219 |
| Number of pages | 27 |
| Journal | Clinics in Geriatric Medicine |
| Volume | 38 |
| Issue number | 2 |
| Early online date | 8 Apr 2022 |
| DOIs | |
| Publication status | Published - May 2022 |
Keywords
- Aging
- Bone
- Cartilage
- Fibrosis
- Inflammation
- Osteoarthritis
- Pathophysiology
- Treatment targets
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Osteoarthritis pathophysiology: Therapeutic target discovery may require a multifaceted approach. / Vincent, Tonia L.; Alliston, Tamara; Kapoor, Mohit et al.
In: Clinics in Geriatric Medicine, Vol. 38, No. 2, 05.2022, p. 193-219.Research output: Contribution to journal › Review article › peer-review
TY - JOUR
T1 - Osteoarthritis pathophysiology: Therapeutic target discovery may require a multifaceted approach
AU - Vincent, Tonia L.
AU - Alliston, Tamara
AU - Kapoor, Mohit
AU - Loeser, Richard F.
AU - Troeberg, Linda
AU - Little, Christopher B.
N1 - Funding Information: T.L. Vincent has received research funding to support the STEpUP OA Consortium from Pfizer , Galapagos , Fidia , Novartis , BioSplice . T. Alliston, M. Kapoor and L. Troeberg have nothing to disclose. R.F. Loeser has received consulting fees from Unity Biotechnology. C.B. Little has provided consulting advice for Merck Serono and Galapagos Pharmaceuticals, and has received research funding from numerous pharmaceutical companies through specific services/testing contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. Funding Information: The research of the authors related to the specific topics explored in this review were supported by funding from numerous sources: T.L. Vincent Center for OA Pathogenesis versus Arthritis (grant no. 20205 and 21,621); M. Kapoor Tier 1 Canada Research Chair Award (#950?232237) and Tony and Shari Fell Platinum Chair in Arthritis Research; R.F. Loeser National Institute on Aging RO1 AG044034; L. Troeberg VA grants 21,776 and 22,194; C.B. Little Australian National Health and Medical Research Council (NHMRC: Project Grant APP1045890), the Hillcrest Foundation through Perpetual Philanthropies, and Arthritis Australia.T.L. Vincent has received research funding to support the STEpUP OA Consortium from Pfizer, Galapagos, Fidia, Novartis, BioSplice. T. Alliston, M. Kapoor and L. Troeberg have nothing to disclose. R.F. Loeser has received consulting fees from Unity Biotechnology. C.B. Little has provided consulting advice for Merck Serono and Galapagos Pharmaceuticals, and has received research funding from numerous pharmaceutical companies through specific services/testing contract research agreements between and managed by The University of Sydney or the Northern Sydney Local Health District. Funding Information: The research of the authors related to the specific topics explored in this review were supported by funding from numerous sources: T.L. Vincent Center for OA Pathogenesis versus Arthritis (grant no. 20205 and 21,621 ); M. Kapoor Tier 1 Canada Research Chair Award (#950–232237) and Tony and Shari Fell Platinum Chair in Arthritis Research; R.F. Loeser National Institute on Aging RO1 AG044034 ; L. Troeberg VA grants 21,776 and 22,194; C.B. Little Australian National Health and Medical Research Council (NHMRC: Project Grant APP1045890), the Hillcrest Foundation through Perpetual Philanthropies, and Arthritis Australia.
PY - 2022/5
Y1 - 2022/5
KW - Aging
KW - Bone
KW - Cartilage
KW - Fibrosis
KW - Inflammation
KW - Osteoarthritis
KW - Pathophysiology
KW - Treatment targets
UR - http://www.scopus.com/inward/record.url?scp=85127781285&partnerID=8YFLogxK
U2 - 10.1016/j.cger.2021.11.015
DO - 10.1016/j.cger.2021.11.015
M3 - Review article
AN - SCOPUS:85127781285
VL - 38
SP - 193
EP - 219
JO - Clinics in Geriatric Medicine
JF - Clinics in Geriatric Medicine
SN - 0749-0690
IS - 2
ER -